Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.


“I find MedCity News a great resource for taking the pulse of the market and sourcing potential investment opportunities.”

Bernie Rudnick, Angel investor and advisor, CapGenic Advisors, LLC


Sign up for our daily newsletter


FDA grants Ethicon Endo-Surgery’s appeal on sedation system

3:23 pm by | 0 Comments

The Food and Drug Administration has reconsidered its denial of Ethicon Endo-Surgery Inc.’s application to begin selling a computer-assisted sedation system.

The move provides an opening for the Cincinnati-based surgical products company to commercialize its Sedasys system, though the FDA still needs to approve Ethicon’s application before that can happen. The system couples physiological patient monitoring with personalized drug delivery, and could help reduce risks associated with sedation, according to Ethicon.

A new independent FDA advisory panel will be appointed to vote on Ethicon’s Premarket Approval Application (PMA), though its vote isn’t binding, which Ethicon knows all too well.

A previous advisory committee already voted in favor of the application. The key word is “advisory.”  If the FDA approves the application, the company would be free to begin selling the Sedasys in the United States.

Advertisement

The FDA denied the system due to objections to the company’s proposed labeling for the device. The labeling would allow gastroenterologist and nurse teams to administer the sedative drug propofol without an anesthesia professional present.

The Sedasys system has received regulatory approval for sale in the European Union, Australia and Canada, according to the company.

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Brandon Glenn

By Brandon Glenn MedCity News

Brandon Glenn is the Ohio bureau chief for MedCity News.
More posts by Author

0 comments

Hear the latest news first

Get our daily newsletter or follow us.

 

Advertisement